Drug repositioning for Alzheimer's disease - PubMed (original) (raw)

. 2012 Nov;11(11):833-46.

doi: 10.1038/nrd3869.

James Pickett, Alistair Burns, Jonathan Corcoran, Stephen B Dunnett, Paul Edison, Jim J Hagan, Clive Holmes, Emma Jones, Cornelius Katona, Ian Kearns, Patrick Kehoe, Amrit Mudher, Anthony Passmore, Nicola Shepherd, Frank Walsh, Clive Ballard

Affiliations

Drug repositioning for Alzheimer's disease

Anne Corbett et al. Nat Rev Drug Discov. 2012 Nov.

Abstract

Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. Given the recent failures of various novel disease-modifying therapies in clinical trials, a complementary strategy based on repositioning drugs that are approved for other indications could be attractive. Indeed, a substantial body of preclinical work indicates that several classes of such drugs have potentially beneficial effects on Alzheimer's-like brain pathology, and for some drugs the evidence is also supported by epidemiological data or preliminary clinical trials. Here, we present a formal consensus evaluation of these opportunities, based on a systematic review of published literature. We highlight several compounds for which sufficient evidence is available to encourage further investigation to clarify an optimal dose and consider progression to clinical trials in patients with Alzheimer's disease.

PubMed Disclaimer

References

    1. Arch Neurol. 2011 Jan;68(1):51-7 -PubMed
    1. Nat Rev Drug Discov. 2004 Aug;3(8):673-83 -PubMed
    1. Expert Rev Neurother. 2011 Mar;11(3):327-9 -PubMed
    1. Arch Neurol. 2012 Jan;69(1):29-38 -PubMed
    1. BMJ. 2010 Jan 12;340:b5465 -PubMed

Publication types

MeSH terms

LinkOut - more resources